A Phase 1 interventional study of MT-1186 and Rosuvastatin in Healthy Adult Subjects, sponsored by Shionogi. Completed at 1 site in Japan. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Shionogi · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional screening criteria check may apply for qualification:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group 1 of Cohort 1: A single-sequence study in which healthy male subjects receive a single dose of rosuvastatin on Day 1 followed by a single dose of sildenafil on Day 4. MT-1186 will be administered from Day 6 to 13 with co-administration of rosuvastatin and sildenafil on Day 9 and 12, respectively.
Drug: MT-1186 · Drug: Rosuvastatin · Drug: Sildenafil
Group 2 of Cohort 1: A single-sequence study in which healthy male subjects receive a single dose of furosemide on Day 1. MT-1186 will be administered from Day 3 to 7 with co-administration of furosemide on Day 6.
Drug: MT-1186 · Drug: Furosemide
Cohort 2: A three-way crossover study in which Japanese healthy male subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 4, and 7 according to their treatment sequence with 3-day wash out between doses. Caucasian healthy male subjects receive a single dose of MT-1186 at the same period with Japanese subjects under the corresponding condition on Day 1, 4, or 7 according to their treatment schedule.
Drug: MT-1186
Suspension
Also known as: Edaravone
Tablets
Also known as: Crestor
Tablets
Also known as: Viagra
Tablets
Also known as: Lasix
Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Rosuvastatin, Sildenafil and Furosemide.
Time frame: Before rosuvastatin dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before sildenafil dosing and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before furosemide dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose
Maximum Plasma Concentration (Cmax) of Rosuvastatin, Sildenafil and Furosemide.
Time frame: Before rosuvastatin dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before sildenafil dosing and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before furosemide dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose
Tmax of Rosuvastatin, Sildenafil and Furosemide.
Time frame: Before rosuvastatin dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before sildenafil dosing and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before furosemide dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose
T1/2 of Rosuvastatin, Sildenafil and Furosemide.
Time frame: Before rosuvastatin dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before sildenafil dosing and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before furosemide dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose
AUC0-inf of Unchanged Edaravone.
Time frame: Group 1 (Day 6, 9 and 12) and Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Cmax of Unchanged Edaravone.
Time frame: Group 1 (Day 6, 9 and 12) and Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Tmax of Unchanged Edaravone.
Time frame: Group 1 (Day 6, 9 and 12) and Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
T1/2 of Unchanged Edaravone.
Time frame: Group 1 (Day 6, 9 and 12) and Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
AUC0-inf of Sulfate Conjugate.
Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Cmax of Sulfate Conjugate.
Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Tmax of Sulfate Conjugate.
Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
T1/2 of Sulfate Conjugate.
Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
AUC0-inf of Glucuronide Conjugate.
Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Cmax of Glucuronide Conjugate.
Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Tmax of Glucuronide Conjugate.
Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
T1/2 of Glucuronide Conjugate.
Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
AUC0-inf of Unchanged Edaravone.
Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Cmax of Unchanged Edaravone.
Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Tmax of Unchanged Edaravone.
Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
T1/2 of Unchanged Edaravone.
Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
AUCinf of Sulfate Conjugate and Glucuronide Conjugate.
Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Cmax of Sulfate Conjugate and Glucuronide Conjugate.
Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Tmax of Sulfate Conjugate and Glucuronide Conjugate.
Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
T1/2 of Sulfate Conjugate and Glucuronide Conjugate.
Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
T1/2 of Glucuronide Conjugate.
Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Number of Participants With Adverse Events and Adverse Drug Reactions
Time frame: Day 1 to 20 in group 1 of cohort 1, Day 1 to 14 in group 2 of cohort 1, Day 1 to 14 of cohort 2
AUCinf of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate.
Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Cmax of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate.
Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Tmax of Unchanged Edaravone.
Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
T1/2 of Unchanged Edaravone.
Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
| Milestone | Rosuvastatin, Sildenafil, and Edaravone Group 1 of Cohort 1 | Furosemide and Edaravone Group 2 of Cohort 1 | Edaravone Group 3 of Cohort 2 | Edaravone Group 4 of Cohort 2 | Edaravone Group 5 of Cohort 2 | Caucasian Group of Cohort 2 |
|---|---|---|---|---|---|---|
| Started | 32 | 34 | 3 | 3 | 3 | 3 |
| Completed | 31 | 34 | 3 | 3 | 3 | 3 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Rosuvastatin, Sildenafil, and Edaravone Group 1 of Cohort 1 | Furosemide and Edaravone Group 2 of Cohort 1 | Edaravone Group 3 of Cohort 2 | Edaravone Group 4 of Cohort 2 | Edaravone Group 5 of Cohort 2 | Caucasian Group of Cohort 2 |
|---|---|---|---|---|---|---|
| Started | 31 | 34 | 3 | 3 | 3 | 3 |
| Completed | 31 | 34 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Rosuvastatin, Sildenafil, and Edaravone Group 1 of Cohort 1 | Furosemide and Edaravone Group 2 of Cohort 1 | Edaravone Group 3 of Cohort 2 | Edaravone Group 4 of Cohort 2 | Edaravone Group 5 of Cohort 2 | Caucasian Group of Cohort 2 |
|---|---|---|---|---|---|---|
| Started | 31 | 0 | 3 | 3 | 3 | 3 |
| Completed | 31 | 0 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| ng*h/mL | Rosuvastatin Alone: Group 1 of Cohort 1 | Rosubastatin + Edaravone: Group 1 of Cohort 1 | Sildenafil Alone: Group 1 of Cohort 1 | Sildenafil + Edaravone: Group 1 of Cohort 1 | Furosemide Alone: Group 2 of Cohort 1 | Furosemide + Edaravone: Group 2 of Cohort 1 |
|---|---|---|---|---|---|---|
| Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Rosuvastatin, Sildenafil and Furosemide. | 161 ± 66.8 | 165 ± 60.2 | 532 ± 236 | 482 ± 195 | 3861 ± 1031 | 3906 ± 736.2 |
| ng/mL | Rosuvastatin Alone: Group 1 of Cohort 1 | Rosubastatin + Edaravone: Group 1 of Cohort 1 | Sildenafil Alone: Group 1 of Cohort 1 | Sildenafil + Edaravone: Group 1 of Cohort 1 | Furosemide Alone: Group 2 of Cohort 1 | Furosemide + Edaravone: Group 2 of Cohort 1 |
|---|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Rosuvastatin, Sildenafil and Furosemide. | 11.3 ± 5.0 | 11.3 ± 5.0 | 232 ± 135 | 201 ± 97.9 | 1676 ± 777.7 | 1701 ± 506.5 |
| h | Rosuvastatin Alone: Group 1 of Cohort 1 | Rosubastatin + Edaravone: Group 1 of Cohort 1 | Sildenafil Alone: Group 1 of Cohort 1 | Sildenafil + Edaravone: Group 1 of Cohort 1 | Furosemide Alone: Group 2 of Cohort 1 | Furosemide + Edaravone: Group 2 of Cohort 1 |
|---|---|---|---|---|---|---|
| Tmax of Rosuvastatin, Sildenafil and Furosemide. | 4.6 ± 1.5 | 5.1 ± 1.4 | 0.8 ± 0.4 | 0.9 ± 0.5 | 1.7 ± 1.1 | 1.8 ± 1.1 |
| h | Rosuvastatin Alone: Group 1 of Cohort 1 | Rosubastatin + Edaravone: Group 1 of Cohort 1 | Sildenafil Alone: Group 1 of Cohort 1 | Sildenafil + Edaravone: Group 1 of Cohort 1 | Furosemide Alone: Group 2 of Cohort 1 | Furosemide + Edaravone: Group 2 of Cohort 1 |
|---|---|---|---|---|---|---|
| T1/2 of Rosuvastatin, Sildenafil and Furosemide. | 14.4 ± 4.0 | 12.1 ± 2.2 | 2.8 ± 1.1 | 3.5 ± 1.4 | 6.9 ± 3.5 | 5.8 ± 3.8 |
| ng*h/mL | Rosuvastatin, Sildenafil, and Edaravone: Group 1 of Cohort 1 | Furosemide and Edaravone: Group 2 of Cohort 1 |
|---|---|---|
| Day 3: Group 2 (Edaravone alone) | — | 2535 ± 919 |
| Day 6: Group 1 (Edaravpne alone), Group 2 (Edaravone + Furosemide) | 2616 ± 730 | 2746 ± 1015 |
| Day 9: Group 1 (Edaravone + Rosuvastatin), Group 2 Not Applicable | 2591 ± 671 | — |
| Day 12: Group 1 (Edaravone + Sildenafil), Group 2 Not Applicable | 2656 ± 712 | — |
| ng/mL | Group 1 of Cohort 1 | Furosemide and Edaravone: Group 2 of Cohort 1 |
|---|---|---|
| Day 3: Group 2 (Edaravone alone) | — | 2180 ± 1035 |
| Day 6: Group 1 (Edaravpne alone), Group 2 (Edaravone + Furosemide) | 2724 ± 1533 | 2074 ± 1051 |
| Day 9: Group 1 (Edaravone + Rosuvastatin) | 2302 ± 943 | — |
| Day 12: Group 1 (Edaravone + Sildenafil) | 2455 ± 1111 | — |
| h | Group 1 of Cohort 1 | Furosemide and Edaravone: Group 2 of Cohort 1 |
|---|---|---|
| Day 3: Group 2 (Edaravone alone) | — | 0.34 ± 0.19 |
| Day 6: Group 1 (Edaravpne alone), Group 2 (Edaravone + Furosemide) | 0.30 ± 0.10 | 0.34 ± 0.17 |
| Day 9: Group 1 (Edaravone + Rosuvastatin) | 0.34 ± 0.13 | — |
| Day 12: Group 1 (Edaravone + Sildenafil) | 0.32 ± 0.17 | — |
| h | Group 1 of Cohort 1 | Furosemide and Edaravone: Group 2 of Cohort 1 |
|---|---|---|
| Day 3: Group 2 (Edaravone alone) | — | 4.67 ± 0.92 |
| Day 6: Group 1 (Edaravpne alone), Group 2 (Edaravone + Furosemide) | 5.23 ± 1.11 | 5.52 ± 0.60 |
| Day 9: Group 1 (Edaravone + Rosuvastatin) | 6.60 ± 1.18 | — |
| Day 12: Group 1 (Edaravone + Sildenafil) | 6.69 ± 1.31 | — |
| ng*h/mL | Group 2 of Cohort 1 |
|---|---|
| Day 3: Group 2 (Edaravone alone) | 26576 ± 6820 |
| Day 6: Group 2 (Edaravone + Furosemide) | 30588 ± 7064 |
| ng/mL | Group 2 of Cohort 1 |
|---|---|
| Day 3: Group 2 (Edaravone alone) | 8115 ± 1775 |
| Day 6: Group 2 (Edaravone + Furosemide) | 8702 ± 2147 |
| h | Group 2 of Cohort 1 |
|---|---|
| Day 3: Group 2 (Edaravone alone) | 0.76 ± 0.28 |
| Day 6: Group 2 (Edaravone + Furosemide) | 0.81 ± 0.30 |
| h | Group 2 of Cohort 1 |
|---|---|
| Day 3: Group 2 (Edaravone alone) | 3.89 ± 0.25 |
| Day 6: Group 2 (Edaravone + Furosemide) | 4.20 ± 0.33 |
| ng*h/mL | Group 2 of Cohort 1 |
|---|---|
| Day 3: Group 2 (Edaravone alone) | 4817 ± 1282 |
| Day 6: Group 2 (Edaravone + Furosemide) | 4953 ± 1285 |
| ng/mL | Group 2 of Cohort 1 |
|---|---|
| Day 3: Group 2 (Edaravone alone) | 2318 ± 649 |
| Day 6: Group 2 (Edaravone + Furosemide) | 2304 ± 694 |
| h | Group 2 of Cohort 1 |
|---|---|
| Day 3: Group 2 (Edaravone alone) | 0.61 ± 0.26 |
| Day 6: Group 2 (Edaravone + Furosemide) | 0.57 ± 0.18 |
| h | Group 2 of Cohort 1 |
|---|---|
| Day 3: Group 2 (Edaravone alone) | 3.65 ± 0.28 |
| Day 6: Group 2 (Edaravone + Furosemide) | 3.97 ± 0.31 |
| ng*h/mL | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 1 Hour After a High-fat Meal | Edaravone Single Dose 4 Hours After a High-fat Meal |
|---|---|---|---|
| AUC0-inf of Unchanged Edaravone. | 1647 ± 433 | 1475 ± 658 | 1247 ± 425 |
| ng/mL | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 1 Hour After a High-fat Meal | Edaravone Single Dose 4 Hours After a High-fat Meal |
|---|---|---|---|
| Cmax of Unchanged Edaravone. | 1810 ± 849.8 | 1502 ± 1272 | 1012 ± 603.3 |
| h | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 1 Hour After a High-fat Meal | Edaravone Single Dose 4 Hours After a High-fat Meal |
|---|---|---|---|
| Tmax of Unchanged Edaravone. | 0.25 (0.25 to 1.00) | 0.50 (0.25 to 1.50) | 0.25 (0.25 to 1.00) |
| h | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 1 Hour After a High-fat Meal | Edaravone Single Dose 4 Hours After a High-fat Meal |
|---|---|---|---|
| T1/2 of Unchanged Edaravone. | 9.33 ± 4.87 | 9.65 ± 5.41 | 7.66 ± 4.12 |
| ng*h/mL | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 1 Hour After a High-fat Meal | Edaravone Single Dose 4 Hours After a High-fat Meal |
|---|---|---|---|
| Sulfate conjugate | 24484 ± 5861 | 22689 ± 6334 | 23022 ± 5094 |
| Glucuronide conjugate | 4178 ± 873 | 4099 ± 637 | 3557 ± 879 |
| ng/mL | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 1 Hour After a High-fat Meal | Edaravone Single Dose 4 Hours After a High-fat Meal |
|---|---|---|---|
| Sulfate conjugate | 8394 ± 1609 | 7802 ± 1556 | 8152 ± 1731 |
| Glucuronide conjugate | 2391 ± 508 | 2176 ± 475 | 1924 ± 380 |
| h | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 1 Hour After a High-fat Meal | Edaravone Single Dose 4 Hours After a High-fat Meal |
|---|---|---|---|
| Sulfate conjugate | 0.67 ± 0.25 | 0.91 ± 0.39 | 0.72 ± 0.26 |
| Glucuronide conjugate | 0.53 ± 0.20 | 0.76 ± 0.35 | 0.72 ± 0.26 |
| h | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 1 Hour After a High-fat Meal | Edaravone Single Dose 4 Hours After a High-fat Meal |
|---|---|---|---|
| Sulfate conjugate | 10.50 ± 7.67 | 7.53 ± 3.55 | 7.55 ± 2.47 |
| Glucuronide conjugate | 4.26 ± 0.38 | 3.89 ± 0.79 | 3.88 ± 0.55 |
| h | Japanese | White |
|---|---|---|
| T1/2 of Glucuronide Conjugate. | 4.26 ± 0.38 | 4.35 ± 0.25 |
| Participants | Rosuvastatin Alone: Group 1 of Cohort 1 | Sildenafil Alone: Group 1 of Cohort 1 | Edaravone Alone: Group 1 of Cohort 1 | Edaravone + Rosuvastatin: Group 1 of Cohort 1 | Edaravone + Sildenafil: Group 1 of Cohort 1 | Combined: After Day 6: Group 1 of Cohort 1 | Furosemide Alone: Group 2 of Cohort 1 | Edaravone Alone: Group 2 of Cohort 1 | Edaravone + Furosemide: Group 2 of Cohort 1 | Combined : After Day 3: Group 2 of Cohort 1 | Edaravone Single Dose Under Fasting Condition: Japanese Conmibed | Edaravone Single Dose 1 Hour After a High-fat Meal: Japanese Conmibed | Edaravone Single Dose 4 Hours After a High-fat Meal: Japanese Conmibed | Edaravone Single Dose Under Fasting Condition: White Conbined |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants with Adverse events | 0 | 2 | 0 | 6 | 3 | 8 | 1 | 0 | 7 | 7 | 0 | 2 | 0 | 0 |
| Number of Participants with adverse drug reactions | 0 | 0 | 0 | 5 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| ng*h/mL | Japanese | White |
|---|---|---|
| Unchanged edaravone | 1647 ± 433 | 1423 ± 391 |
| Sulfate conjugate | 24484 ± 5861 | 20098 ± 1592 |
| Glucuronide conjugate | 4178 ± 873 | 3795 ± 571 |
| ng/mL | Japanese | White |
|---|---|---|
| Unchanged edaravone | 1810 ± 850 | 1484 ± 920 |
| Sulfate conjugate | 8394 ± 1609 | 6530 ± 787 |
| Glucuronide conjugate | 2391 ± 508 | 2136 ± 403 |
| h | Japanese | White |
|---|---|---|
| Unchanged edaravone | 0.4 ± 0.3 | 0.4 ± 0.2 |
| Sulfate conjugate | 0.67 ± 0.25 | 0.67 ± 0.25 |
| Glucuronide conjugate | 0.53 ± 0.20 | 0.61 ± 0.22 |
| h | Japanese | White |
|---|---|---|
| Unchanged edaravone | 9.3 ± 4.9 | 16.2 ± 15.8 |
| Sulfate conjugate | 10.5 ± 7.7 | 10.7 ± 6.5 |
| Glucuronide conjugate | 4.3 ± 0.4 | 4.4 ± 0.3 |
Collected over Cohort 1 Group 1: Day 1 to Day 20. Cohort 1 Group 2 and Cohort 2: Day 1 to Day 14.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin Alone: Group 1 of Cohort 1 | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) |
| Sildenafil Alone: Group 1 of Cohort 1 | 0/31 (0%) | 0/31 (0%) | 2/31 (6.5%) |
| Edaravone Alone: Group 1 of Cohort 1 | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| Edaravone + Rosuvastatin: Group 1 of Cohort 1 | 0/31 (0%) | 0/31 (0%) | 6/31 (19.4%) |
| Edaravone + Sildenafil: Group 1 of Cohort 1 | 0/31 (0%) | 0/31 (0%) | 3/31 (9.7%) |
| Combined: After Day 6: Group 1 of Cohort 1 | 0/31 (0%) | 0/31 (0%) | 8/31 (25.8%) |
| Furosemide Alone: Group 2 of Cohort 1 | 0/34 (0%) | 0/34 (0%) | 1/34 (2.9%) |
| Edaravone Alone: Group 2 of Cohort 1 | 0/34 (0%) | 0/34 (0%) | 0/34 (0%) |
| Edaravone + Furosemide: Group 2 of Cohort 1 | 0/34 (0%) | 0/34 (0%) | 7/34 (20.6%) |
| Combined : After Day 3: Group 2 of Cohort 1 | 0/34 (0%) | 0/34 (0%) | 7/34 (20.6%) |
| Edaravone Single Dose Under Fasting Condition: Japanese Conmibed | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| Edaravone Single Dose 1 Hour After a High-fat Meal: Japanese Conmibed | 0/9 (0%) | 0/9 (0%) | 2/9 (22.2%) |
| Edaravone Single Dose 4 Hours After a High-fat Meal: Japanese Conmibed | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| Edaravone Single Dose Under Fasting Condition: White Combined | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| Event | Rosuvastatin Alone: Group 1 of Cohort 1 | Sildenafil Alone: Group 1 of Cohort 1 | Edaravone Alone: Group 1 of Cohort 1 | Edaravone + Rosuvastatin: Group 1 of Cohort 1 | Edaravone + Sildenafil: Group 1 of Cohort 1 | Combined: After Day 6: Group 1 of Cohort 1 | Furosemide Alone: Group 2 of Cohort 1 | Edaravone Alone: Group 2 of Cohort 1 | Edaravone + Furosemide: Group 2 of Cohort 1 | Combined : After Day 3: Group 2 of Cohort 1 | Edaravone Single Dose Under Fasting Condition: Japanese Conmibed | Edaravone Single Dose 1 Hour After a High-fat Meal: Japanese Conmibed | Edaravone Single Dose 4 Hours After a High-fat Meal: Japanese Conmibed | Edaravone Single Dose Under Fasting Condition: White Combined |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/32 | 0/31 | 0/31 | 1/31 | 2/31 | 3/31 | 0/34 | 0/34 | 0/34 | 0/34 | 0/9 | 2/9 | 0/9 | 0/9 |
| AnaemiaBlood and lymphatic system disorders | 0/32 | 0/31 | 0/31 | 0/31 | 0/31 | 0/31 | 0/34 | 0/34 | 5/34 | 5/34 | 0/9 | 0/9 | 0/9 | 0/9 |
| DiarrhoeaGastrointestinal disorders | 0/32 | 0/31 | 0/31 | 4/31 | 0/31 | 4/31 | 0/34 | 0/34 | 0/34 | 0/34 | 0/9 | 0/9 | 0/9 | 0/9 |
| Aspartate aminotransferase increasedInvestigations | 0/32 | 0/31 | 0/31 | 1/31 | 0/31 | 1/31 | 0/34 | 0/34 | 0/34 | 0/34 | 0/9 | 1/9 | 0/9 | 0/9 |
| Blood creatine phosphokinase increasedInvestigations | 0/32 | 0/31 | 0/31 | 0/31 | 0/31 | 0/31 | 0/34 | 0/34 | 0/34 | 0/34 | 0/9 | 1/9 | 0/9 | 0/9 |
| Blood lactate dehydrogenase increasedInvestigations | 0/32 | 0/31 | 0/31 | 0/31 | 0/31 | 0/31 | 0/34 | 0/34 | 0/34 | 0/34 | 0/9 | 1/9 | 0/9 | 0/9 |
| HeadacheNervous system disorders | 0/32 | 2/31 | 0/31 | 0/31 | 0/31 | 0/31 | 1/34 | 0/34 | 3/34 | 3/34 | 0/9 | 0/9 | 0/9 | 0/9 |
| Abnormal sensation in eyeEye disorders | 0/32 | 0/31 | 0/31 | 0/31 | 1/31 | 1/31 | 0/34 | 0/34 | 0/34 | 0/34 | 0/9 | 0/9 | 0/9 | 0/9 |
| PalpitationsCardiac disorders | 0/32 | 0/31 | 0/31 | 1/31 | 0/31 | 1/31 | 0/34 | 0/34 | 0/34 | 0/34 | 0/9 | 0/9 | 0/9 | 0/9 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/32 | 1/31 | 0/31 | 0/31 | 0/31 | 0/31 | 0/34 | 0/34 | 0/34 | 0/34 | 0/9 | 0/9 | 0/9 | 0/9 |
| Age, Categorical(Participants) | Rosuvastatin, Sildenafil, and Edaravone Group 1 of Cohort 1 | Furosemide and Edaravone Group 2 of Cohort 1 | Japanese Combined of Cohort 2 | Caucasian Group of Cohort 2 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 32 | 34 | 9 | 9 | 84 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Rosuvastatin, Sildenafil, and Edaravone Group 1 of Cohort 1 | Furosemide and Edaravone Group 2 of Cohort 1 | Japanese Combined of Cohort 2 | Caucasian Group of Cohort 2 | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 32 | 34 | 9 | 9 | 84 |
| Race (NIH/OMB)(Participants) | Rosuvastatin, Sildenafil, and Edaravone Group 1 of Cohort 1 | Furosemide and Edaravone Group 2 of Cohort 1 | Japanese Combined of Cohort 2 | Caucasian Group of Cohort 2 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 32 | 34 | 9 | 0 | 75 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 9 | 9 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in Dec 2018, 2 months.
Results were first posted in Aug 2024, 5 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edaravone